These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 29477077)

  • 1. Pan-NS3 protease inhibitors of hepatitis C virus based on an R
    Belfrage AK; Abdurakhmanov E; Åkerblom E; Brandt P; Alogheli H; Neyts J; Danielson UH; Sandström A
    Eur J Med Chem; 2018 Mar; 148():453-464. PubMed ID: 29477077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.
    Belfrage AK; Abdurakhmanov E; Kerblom E; Brandt P; Oshalim A; Gising J; Skogh A; Neyts J; Danielson UH; Sandström A
    Bioorg Med Chem; 2016 Jun; 24(12):2603-20. PubMed ID: 27160057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of achiral inhibitors of the hepatitis C virus NS3 protease based on 2(1H)-pyrazinones.
    Ortqvist P; Gising J; Ehrenberg AE; Vema A; Borg A; Karlén A; Larhed M; Danielson UH; Sandström A
    Bioorg Med Chem; 2010 Sep; 18(17):6512-25. PubMed ID: 20673728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.
    Ren J; Ojeda I; Patel M; Johnson ME; Lee H
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2349-2353. PubMed ID: 31201062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achiral pyrazinone-based inhibitors of the hepatitis C virus NS3 protease and drug-resistant variants with elongated substituents directed toward the S2 pocket.
    Gising J; Belfrage AK; Alogheli H; Ehrenberg A; Åkerblom E; Svensson R; Artursson P; Karlén A; Danielson UH; Larhed M; Sandström A
    J Med Chem; 2014 Mar; 57(5):1790-801. PubMed ID: 23517538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
    Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J
    Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
    Lampa A; Ehrenberg AE; Gustafsson SS; Vema A; Kerblom E; Lindeberg G; Karlén A; Danielson UH; Sandström A
    Bioorg Med Chem; 2010 Jul; 18(14):5413-24. PubMed ID: 20541424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors.
    Ehrenberg AE; Schmuck B; Anwar MI; Gustafsson SS; Stenberg G; Danielson UH
    J Enzyme Inhib Med Chem; 2014 Dec; 29(6):868-76. PubMed ID: 24517372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
    Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease.
    Nagpal N; Goyal S; Wahi D; Jain R; Jamal S; Singh A; Rana P; Grover A
    Gene; 2015 Oct; 570(1):115-21. PubMed ID: 26055089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.
    Massariol MJ; Zhao S; Marquis M; Thibeault D; White PW
    Biochem Biophys Res Commun; 2010 Jan; 391(1):692-7. PubMed ID: 19944069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.
    Vidal LL; Soares MA; Santos AF
    J Viral Hepat; 2016 Nov; 23(11):840-849. PubMed ID: 26775769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.
    Vallet S; Viron F; Henquell C; Le Guillou-Guillemette H; Lagathu G; Abravanel F; Trimoulet P; Soussan P; Schvoerer E; Rosenberg A; Gouriou S; Colson P; Izopet J; Payan C;
    Antivir Ther; 2011; 16(7):1093-102. PubMed ID: 22024525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
    McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
    J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of HCV protease inhibitors.
    Chen KX; Njoroge FG
    Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435.
    Xue W; Pan D; Yang Y; Liu H; Yao X
    Antiviral Res; 2012 Jan; 93(1):126-37. PubMed ID: 22127068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.
    Boloor A; Hanway D; Joshi M; Winn DT; Mendez G; Walls M; Wei P; Qian F; Zhang X; Zhang Y; Hepperle ME; Li X; Campbell DA; Betancort JM
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5708-11. PubMed ID: 19713109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent aza-peptide derived inhibitors of HCV NS3 protease.
    Venkatraman S; Wu W; Shih NY; George Njoroge F
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4760-3. PubMed ID: 19596195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of potent nucleotide-mimicking competitive inhibitors of hepatitis C virus NS3 helicase.
    Gemma S; Butini S; Campiani G; Brindisi M; Zanoli S; Romano MP; Tripaldi P; Savini L; Fiorini I; Borrelli G; Novellino E; Maga G
    Bioorg Med Chem Lett; 2011 May; 21(9):2776-9. PubMed ID: 20880703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.